DMII · Drugs Made In America Acquisition II Corp.
$10.12
+0.02 (+0.15%)
At close · Jul 28
Going-concern doubt
— flagged May 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“In connection with our assessment of going concern considerations in accordance with Financial Accounting Standard Board's Accounting Standards Update ("ASU") 2014-15, "Disclosures of Uncertainties about an Entity's Ability to Continue as a Going Concern," management has determined that these conditions raise substantial doubt about the Company's ability to continue as a going concern within one year after the date that the financial statements are issued.”View the 10-Q filed May 14, 2026
Market Cap
$644.01M
Shares
63.70M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
No Compensation Data
No Summary Compensation Table has been imported from this company's proxy statements yet.
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Roger Bendelac | Chief Executive Officer | Appointed | 2026-03-06 |
| Lynn Stockwell | member of the Board | Resigned | 2026-03-06 |
| Lynn Stockwell | Executive Chair of the Board | Resigned | 2026-03-06 |
| Lynn Stockwell | Chief Executive Officer | Resigned | 2026-03-06 |
Key facts
CIK
2040475
CUSIP
G2851K104
13F (30d)
5 filings
5 filers